Navigation Links
Aperion Biologics Initiates Clinical Trial of Z-Lig™ Device for Anterior Cruciate Ligament Reconstruction

SAN ANTONIO, Feb. 11, 2011 /PRNewswire/ -- Aperion Biologics, Inc. announced the enrollment and implantation of the first patients in the Company's clinical trial of its Z-Lig™ Anterior Cruciate Ligament Reconstruction (ACLR) Device for the treatment of ligament injuries of the knee.  The primary objective of the multicenter study is to provide additional evidence of the safety and performance of Z-Lig in the reconstruction of patients' knees with primary ACL ruptures.  Seven sites in Europe and one site in South Africa are participating in this clinical trial.  Dr. Willem van der Merwe of the Sports Science Orthopaedic Clinic in Cape Town, South Africa said, "We are pleased to be part of this cutting-edge study.  Graft options are limited for ligament reconstruction procedures and Z-Lig could prove to be a tissue alternative which would enhance the world of ACL reconstruction surgeries."  The study results will be used to support regulatory approvals and clinical acceptance of the Z-Lig ACLR device in select markets outside of the United States.

"Initiating the Z-Lig ACLR clinical trial is an important step not only for our technology and the Company but also for the field of orthopaedics," said Daniel R. Lee, Aperion Biologics' CEO.  "Z-Lig ACLR represents an opportunity to provide a biologic graft sourced from non-human tissue.  This device is a functional scaffold which supports the regeneration of the patient's own tissue.  It has been a long-standing goal for surgeons and the industry globally to have a readily available, off-the-shelf ACL graft."

The ACL is the most commonly injured knee ligament.  Over 800,000 knee ligament reconstruction surgeries are estimated to be performed each year worldwide.

Further information on the Z-Lig study is also available on

About  Z-Lig

Aperion's Z-Lig is a proprietary immunochemically modified porcine tissue-based, sterile medical device for implantation to reconstruct a ruptured Anterior Cruciate Ligament (ACL).  Z-Lig is the only known biological alternative to human tissue for ACL replacement in clinical evaluation.  Since Z-Lig is a biological implant that maintains a mechanically stable scaffold, it can become populated and remodeled with the patient's own cells (similar to human-sourced tissue).  Aperion previously completed a clinical study for Z-Lig in the U.S. in which the grafts successfully demonstrated safety and feasibility during the two-year evaluation.

About Aperion Biologics, Inc.

Aperion Biologics, Inc., located in San Antonio, Texas, is a privately owned, clinical-stage medical device company addressing the need for alternatives to human-based grafts with animal-based tissue technology.  Aperion has developed and patented a technique to make animal tissues usable for human applications without causing rejection.  The core platform technology is an enzymatic stripping of the key carbohydrate antigens followed by a unique conversion process that both "humanizes" and sterilizes the tissues without adversely affecting their biomechanical or biological properties.  This tissue scaffold provides mechanical stability and function while being biologically integrated and remodeled.  Aperion's Z-Process™ of humanizing and sterilizing tissue is applicable to a variety of tissues used in orthopaedic, cardiovascular, plastic, dermatologic, general and other surgical specialties.

SOURCE Aperion Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. New Oral Biologics Delivery Company, Entrega, Announces Strategic Partnership with Pharma
2. Reportlinker Adds Biotechnology Industry 2010 Yearbook - Top Biologics, Biosimilars, Licensing and Financing, Mergers and Acquisitions
3. Dendreon Submits Post-Approval Supplement to the PROVENGE Biologics License Application for New Jersey Manufacturing Facility
4. Reportlinker Adds Immunogenicity to Biologics
5. Reportlinker Adds Downstream Processing in Biopharmaceuticals - Increased Demand for Biologics Drives Improvement in Cost -effective Purification Technologies
6. Crescendo Biologics Announces First Triple Knockout Mouse
7. Immune Biosimilars Will Erode $10.8 Billion in Immune Biologics Brand Sales in 2019 Across the U.S., EU5 and Japan
8. Edimer Pharmaceuticals and CMC Biologics Announce Agreement to Manufacture EDI200 Recombinant Protein
9. Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies
10. Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential
11. Bone Biologics Announces a Major US Patent Issuance For Its Recombinant Protein Process For the Formation of Cartilage
Post Your Comments:
(Date:6/27/2016)... , ... June 27, 2016 , ... ... bring innovative medical technologies, services and solutions to the healthcare market. The company's ... of various distribution, manufacturing, sales and marketing strategies that are necessary to help ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:6/2/2016)... June 2, 2016   The Weather Company , an ... Ads, an industry-first capability in which consumers will be able ... to ask questions via voice or text and receive relevant ... Marketers have long sought an advertising solution ... can be personal, relevant and valuable; and can scale across ...
(Date:5/24/2016)... 2016 Ampronix facilitates superior patient care by providing unparalleled technology to leaders ... is the latest premium product recently added to the range of products distributed by ... ... ... LCD Medical Display- Ampronix News ...
(Date:5/12/2016)... , May 12, 2016 ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
Breaking Biology News(10 mins):